Exagen Inc reports results for the quarter ended in December - Earnings Summary

Exagen

18/03/2024 13:31

* Exagen Inc  XGN.OQ  reported a quarterly adjusted loss
of 31
cents​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of -83
cents.  The mean expectation of six analysts for the quarter was
for a loss of 43 cents per share. Wall Street expected
results to range from -48 cents to -39 cents per share.
    * Revenue rose 7.2% to $13.77 million from a year ago;
analysts
expected $11.56 million. 
    * Exagen Inc's reported EPS for the quarter was a loss of 31
cents​.
    * The company reported a quarterly loss of $5.57 million.
    * Exagen Inc shares had fallen by 18.6% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for Exagen Inc is
$5.50 
This summary was machine generated from LSEG data March 18 at
01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.43          -0.31          Beat
 Sep. 30 2023      -0.47          -0.31          Beat
 Jun. 30 2023      -0.49          -0.28          Beat
 Mar. 31 2023      -0.56          -0.44          Beat